Protocol Ledger

NCT03804944 · Phase II · RECRUITING

Converting HR+ Breast Cancer Into an Individualized Vaccine

Interventional Phase II clinical trial protocol NCT03804944 sponsored by Weill Medical College of Cornell University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-03-17 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03804944
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03804944
Protocol FieldVerified Registry Value
NCT IdentifierNCT03804944
Consolidated Lead SponsorWeill Medical College of Cornell University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2020-03-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03804944
Hospital Research SiteLocationSite Profile
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->
Weill Cornell MedicineNew York, NYOpen Hospital Dossier ->
UPMC Hillman Cancer CenterPittsburgh, PAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI